Previous 10 | Next 10 |
home / stock / nvsef / nvsef news
The following slide deck was published by Novartis AG in conjunction with their 2021 Q4 earnings call. For further details see: Novartis AG 2021 Q4 - Results - Earnings Call Presentation
Fisher’s 13F portfolio value increased from ~$161B to ~$179B in Q4 2021. Amazon, Netflix, Meta Platforms, and PayPal Holdings were increased while reducing Visa, Cisco Systems, Walt Disney, Intel, Wal-Mart, UnitedHealth, and Starbucks this quarter. The top three positions a...
Contrarian idea after the Q4 results. Solid Q4 results. Positive outlook, we rate Novartis as a Buy. For further details see: Novartis: A Good Long-Term Pick
Novartis AG (NVS) Q4 2021 Earnings Conference Call February 02, 2022, 08:00 ET Company Participants Samir Shah - Global Head, IR Vasant Narasimhan - CEO Marie-France Tschudin - President, Novartis Pharmaceuticals Susanne Schaffert - President, Novartis Oncology Harry Kirsch - CFO Richard Sayn...
Novartis is a large cap pharma company from Switzerland with a portfolio that is broadly diversified both in terms of products and in terms of geography. Its three top-selling drugs account for only 17% of 2020 net sales, and Novartis typically generates less than 40% of total sales i...
The year 2021, was relatively mixed for biotech stocks with some posting significant gains while others pulled back dramatically. However, moving into 2022, we could see a significant rebound based on products launched in 2021, or in anticipation of new product announcements. Sage T...
Pharma/biotech is the most attractive subsector. The most overvalued one is life science tools. IXJ: an alternative to XLV. 10 stocks cheaper than their peers in December. For further details see: IXJ: Healthcare Dashboard For December
Kiplinger "insights for investors" online, first-published 91 "Top Dividend Stocks From Around The World" 7/13/20. Two Kiplinger articles provided this 105 Best Dividend Stocks on Earth compiled 7/1/21. 40 European “Dividend Aristocrats,” showed 10 years of stable or inc...
The following slide deck was published by Novartis AG in conjunction with this event. For further details see: Novartis (NVS) R&D Day - Slideshow
FDEU was the 2nd-ranked DxY fund in our recent Quality CEF report. FDEU achieves full distribution coverage through investment into high dividend stocks. However, value and options strategy has caused underperformance vs. benchmark. Wide discount provides an attractive entry p...
News, Short Squeeze, Breakout and More Instantly...
Novartis Ag Basel Akt Company Name:
NVSEF Stock Symbol:
OTCMKTS Market:
Novartis Ag Basel Akt Website:
FDA approval of the company’s second US Radioligand Therapy (RLT) manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyond New 70,000-square foot RLT facility is the company’s largest and most advanced in the world to date and centrall...
APPLY-PNH extension data show that continuous Fabhalta ® (iptacopan) treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH) enabled sustained hemoglobin-level increases to near-normal (≥12 g/dL), blood transfusion avoidance, and improved patient-reported fatigu...
With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali ® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in secondary endpoints including overall survival (OS) 1,2 iDFS...